Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Down 38.5% in January

Guided Therapeutics Inc. (OTCMKTS:GTHP) saw a large drop in short interest in January. As of January 30th, there was short interest totaling 17,754 shares, a drop of 38.5% from the January 15th total of 28,887 shares. Based on an average daily trading volume, of 9,930 shares, the days-to-cover ratio is currently 1.8 days. Approximately 0.1% of the company’s shares are sold short. Approximately 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 9,930 shares, the days-to-cover ratio is currently 1.8 days.

Guided Therapeutics Price Performance

Shares of OTCMKTS:GTHP traded up $0.01 during trading on Friday, reaching $0.32. 23,259 shares of the company were exchanged, compared to its average volume of 7,278. The firm has a market capitalization of $27.74 million, a PE ratio of -6.40 and a beta of 0.61. The business’s fifty day simple moving average is $0.38 and its 200-day simple moving average is $0.30. Guided Therapeutics has a 12-month low of $0.06 and a 12-month high of $0.54.

Guided Therapeutics (OTCMKTS:GTHP) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.06 million during the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.